The massive capital raise (over $600M) provides ADARx with a multi-year cash runway to advance its siRNA pipeline through late-stage clinical milestones. Watch for upcoming clinical data readouts and potential pipeline expansion, as well as any further collaboration announcements with AbbVie.
Price Chart
Executive Summary
ADARx Pharmaceuticals announced the full exercise of the underwriters' option to purchase an additional 3,937,500 shares in its upsized IPO, bringing total shares sold to 30,187,500 and aggregate gross proceeds to approximately $513.2 million. Including a concurrent private placement with AbbVie for 5,255,542 shares at $17.00 per share, total gross proceeds reached approximately $602.5 million. This is a significant capital raise for a late-stage biotech, providing substantial cash runway for its siRNA pipeline.
Key Financial Metrics
Key Facts
- Underwriters fully exercised option to purchase an additional 3,937,500 shares at $17.00 per share.
- Total IPO shares sold: 30,187,500 shares.
- Aggregate gross IPO proceeds: approximately $513.2 million.
- Concurrent private placement with AbbVie: 5,255,542 shares at $17.00 per share.
- Combined gross proceeds from IPO and private placement: approximately $602.5 million.
- IPO registration statements became effective on September 24, 2026.
- Lead book-running managers: J.P. Morgan, Morgan Stanley, TD Cowen, UBS Investment Bank.
- AbbVie collaboration and license option agreement covers siRNA therapeutics across neuroscience, immunology, and oncology.
Financial Impact
Total gross proceeds of approximately $602.5 million from IPO and concurrent private placement.
Risk Factors
- Significant dilution to existing shareholders from the 30.2 million shares sold in the IPO.
- Execution risk in advancing siRNA candidates through clinical trials.
- Reliance on AbbVie collaboration for certain programs; partnership dynamics could shift.
Investment Themes
Documents Analyzed
This report is based on 1 press release from GlobeNewswire.
| Document | Accession Number |
|---|---|
| PRESS-RELEASE Data (Synthetic) | press-3373408 |
Filters
| Type | Now | ||||
|---|---|---|---|---|---|
Oct 16, 2026 10d ago | SC 13G | $17.63 $17.68 | ▲ +0.28% | ▼ −0.05% | $17.81 (+1.02%) |
Oct 5, 2026 21d ago | SC 13D | $18.58 $17.33 | ▼ −6.73% | ▼ −6.49% | $17.81 (−4.14%) |
Oct 2, 2026 24d ago | SC 13D | $19.05 $18.58 | ▼ −2.47% | ▼ −3.02% | $17.81 (−6.51%) |
Oct 1, 2026 25d ago | Press Release | $18.25 $19.05 | ▲ +4.38% | ▲ +3.71% | $17.81 (−2.41%) |
Oct 1, 2026 25d ago | SC 13G | $18.25 $19.05 | ▲ +4.38% | ▲ +3.71% | $17.81 (−2.41%) |
Sep 30, 2026 26d ago | Insider Cluster | $19.54 $18.25 | ▼ −6.60% | ▼ −7.34% | $17.81 (−8.85%) |
Sep 29, 2026 27d ago | Insider Cluster | $19.94 $19.54 | ▼ −2.01% | ▼ −2.18% | $17.81 (−10.68%) |
Sep 25, 2026 4w ago | 424B4 | $20.09 $20.64 | ▲ +2.71% | ▲ +2.90% | $17.81 (−11.35%) |
Sep 25, 2026 4w ago | EFFECT | $19.35 $20.09 | ▲ +3.82% | ▲ +4.57% | $17.81 (−7.96%) |
Sep 24, 2026 4w ago | Press Release | $19.35 $20.09 | ▲ +3.82% | ▲ +4.57% | $17.81 (−7.96%) |
US Market Status
Subscribe to SecBot
Get Real-Time SEC Filing Intelligence
Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.
Create a free account Live analysis, Telegram alerts, watchlists and the MCP server for subscribers